Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023
PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023...
COVID-19
Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process
Combination Test Also Secures Point-Of-Care Authorization in Australia Lucira COVID-19 & Flu Home Test – The First & Only Combination...
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health...
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce...
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance...
Assure Holdings Regains Compliance with NASDAQ Continued Listing Requirements
DENVER, March 24, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
BioSig Announces New Advisory Board Member Lorraine Spurge
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital...
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update
Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization Management to host Investor Day...
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat...
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living...
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,...
CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss...
AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development
Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD,...
Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings
BATON ROUGE, La., March 23, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,...
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of...
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of...
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced...